Who Supplies Gliclazide to India from CANADA

Importing finished pharmaceutical formulations containing Gliclazide into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and licensed. An Import Registration Certificate (Form 40) and an Import License are necessary for each consignment. The registration process involves submitting detailed product information, including manufacturing and quality control data, to CDSCO. The timeline for obtaining these approvals can vary but typically ranges from 3 to 6 months, depending on the completeness of the application and regulatory workload. For formulations under HS Code 30049099, specific requirements include proof of Good Manufacturing Practice (GMP) compliance, stability data, and a No Objection Certificate (NOC) from the manufacturer. It's essential to ensure that all documentation is accurate and complete to avoid delays in the approval process.

Upon arrival in India, imported pharmaceutical formulations containing Gliclazide are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the product's composition, purity, and compliance with specified standards. Stability data, particularly in line with International Council for Harmonisation (ICH) guidelines for Zone IVa/IVb climates, is also required to demonstrate the product's shelf-life and efficacy under Indian conditions. The Indian Pharmacopoeia sets the official standards for quality, purity, and strength. Port inspections by customs drug inspectors are conducted to verify compliance with these standards. If a batch fails to meet the required specifications, it may be rejected, leading to potential delays and financial losses.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the importation of pharmaceutical products to enhance drug safety and efficacy. Notably, on April 8, 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Gliclazide, must obtain both an Import Registration Certificate and an Import License as per the Drugs and Cosmetics Act and Rules. This requirement aims to prevent the sale of unapproved or illegal medicines in the Indian market. Additionally, the introduction of the Production Linked Incentive (PLI) scheme has impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. These policy changes reflect India's commitment to improving the quality and safety of pharmaceutical products available to its population.

India imports finished Gliclazide formulations primarily due to the demand for patented or branded products, specialized dosage forms, and formulations not yet manufactured domestically. The domestic pharmaceutical industry may lack the capacity or technology to produce certain Gliclazide formulations, leading to reliance on imports to meet patient needs. The market size for Gliclazide formulations in India is substantial, driven by the high prevalence of diabetes and the need for effective glycemic control. Imported formulations often offer advantages such as advanced drug delivery systems, improved patient compliance, and established brand recognition, which are valued in the Indian market.